These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Müller F; Kraus E; Holze F; Becker A; Ley L; Schmid Y; Vizeli P; Liechti ME; Borgwardt S Psychopharmacology (Berl); 2022 Jun; 239(6):1933-1943. PubMed ID: 35076721 [TBL] [Abstract][Full Text] [Related]
4. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. Heekeren K; Neukirch A; Daumann J; Stoll M; Obradovic M; Kovar KA; Geyer MA; Gouzoulis-Mayfrank E J Psychopharmacol; 2007 May; 21(3):312-20. PubMed ID: 17591658 [TBL] [Abstract][Full Text] [Related]
5. Management of hallucinogen abuse. Haddad LM Am Fam Physician; 1976 Jul; 14(1):82-7. PubMed ID: 1065215 [TBL] [Abstract][Full Text] [Related]
6. Dependence on LSD and other hallucinogenic drugs. JAMA; 1967 Oct; 202(1):141-4. PubMed ID: 6072003 [No Abstract] [Full Text] [Related]
7. Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach. Lerner AG; Gelkopf M; Skladman I; Oyffe I; Finkel B; Sigal M; Weizman A Isr J Psychiatry Relat Sci; 2002; 39(2):92-9. PubMed ID: 12227234 [TBL] [Abstract][Full Text] [Related]
8. [Synesthesias in the context of hallucinogen-induced persistent perception disorder following the use of lsd]. Neven A; Blom JD Tijdschr Psychiatr; 2014; 56(11):748-52. PubMed ID: 25401683 [TBL] [Abstract][Full Text] [Related]
9. Adverse consequences of lysergic acid diethylamide. Abraham HD; Aldridge AM Addiction; 1993 Oct; 88(10):1327-34. PubMed ID: 8251869 [TBL] [Abstract][Full Text] [Related]
11. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Lerner AG; Gelkopf M; Skladman I; Rudinski D; Nachshon H; Bleich A Int Clin Psychopharmacol; 2003 Mar; 18(2):101-5. PubMed ID: 12598822 [TBL] [Abstract][Full Text] [Related]
12. The adverse effects of hallucinogens from intramural perspective. Frecska E; Luna LE Neuropsychopharmacol Hung; 2006 Dec; 8(4):189-200. PubMed ID: 17211054 [TBL] [Abstract][Full Text] [Related]
13. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. Halpern JH; Lerner AG; Passie T Curr Top Behav Neurosci; 2018; 36():333-360. PubMed ID: 27822679 [TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. Lev-Ran S; Feingold D; Frenkel A; Lerner AG J Dual Diagn; 2014; 10(2):79-83. PubMed ID: 25392249 [TBL] [Abstract][Full Text] [Related]
15. Psilocybin as a discriminative stimulus: lack of specificity in an animal behavior model for 'hallucinogens'. Koerner J; Appel JB Psychopharmacology (Berl); 1982; 76(2):130-5. PubMed ID: 6805022 [TBL] [Abstract][Full Text] [Related]
16. Hallucinogen persisting perception disorder: what do we know after 50 years? Halpern JH; Pope HG Drug Alcohol Depend; 2003 Mar; 69(2):109-19. PubMed ID: 12609692 [TBL] [Abstract][Full Text] [Related]
19. Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021. Keyes KM; Patrick ME Addiction; 2023 Dec; 118(12):2449-2454. PubMed ID: 37287110 [TBL] [Abstract][Full Text] [Related]
20. Flashbacks and HPPD: A Clinical-oriented Concise Review. G Lerner A; Rudinski D; Bor O; Goodman C Isr J Psychiatry Relat Sci; 2014; 51(4):296-301. PubMed ID: 25841228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]